| Dr Thomas Robert Drames, DO | |
|
1000 Floral Vale Blvd, Suite 125, Yardley, PA 19067-5569 | |
| (215) 785-9500 | |
| (215) 785-9470 |
| Full Name | Dr Thomas Robert Drames |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 15 Years |
| Location | 1000 Floral Vale Blvd, Yardley, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003049610 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mary Medical Center | Langhorne, PA | Hospital |
| Nazareth Hospital | Philadelphia, PA | Hospital |
| Hospital Of Univ Of Pennsylvania | Philadelphia, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alliance Cancer Specialists | 7214194091 | 55 |
News Archive
Researchers at the University of Warwick have found that sexual orientation has a real effect on how we perform mental tasks such as navigating with a map in a car but that old age does not discriminate on grounds of sexual orientation and withers all men's minds alike just ahead of women's.
Arlington Medical Resources, a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that electrical cardioversion usage patterns in Europe differed dramatically by country in the fourth quarter of 2009. While ECV represented almost half of all cardioversion attempts in Germany, in Spain ECV accounted for only 13% of cardioversion attempts.
MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, announced today its record revenue results for the third quarter of 2015, its guidance for the fourth quarter of 2015, and that the Company has secured a $50 million Senior Secured Credit Facility.
An assay that identifies a peculiar but important abnormality in cancer cells has been developed and validated by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the first patient has been dosed in a Phase 1/2 study of its vaccine candidate, CDX-1401, in patients with malignant solid tumors that express NY-ESO-1. CDX-1401 is a fully human monoclonal antibody designed to selectively deliver the NY-ESO-1 antigen to dendritic cells to generate a robust immune response against cancer cells expressing NY-ESO-1.
› Verified 6 days ago
| Entity Name | Institute For Respiratory And Sleep Medicine P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164411146 PECOS PAC ID: 0840262713 Enrollment ID: O20040812000356 |
News Archive
Researchers at the University of Warwick have found that sexual orientation has a real effect on how we perform mental tasks such as navigating with a map in a car but that old age does not discriminate on grounds of sexual orientation and withers all men's minds alike just ahead of women's.
Arlington Medical Resources, a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that electrical cardioversion usage patterns in Europe differed dramatically by country in the fourth quarter of 2009. While ECV represented almost half of all cardioversion attempts in Germany, in Spain ECV accounted for only 13% of cardioversion attempts.
MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, announced today its record revenue results for the third quarter of 2015, its guidance for the fourth quarter of 2015, and that the Company has secured a $50 million Senior Secured Credit Facility.
An assay that identifies a peculiar but important abnormality in cancer cells has been developed and validated by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the first patient has been dosed in a Phase 1/2 study of its vaccine candidate, CDX-1401, in patients with malignant solid tumors that express NY-ESO-1. CDX-1401 is a fully human monoclonal antibody designed to selectively deliver the NY-ESO-1 antigen to dendritic cells to generate a robust immune response against cancer cells expressing NY-ESO-1.
› Verified 6 days ago
| Entity Name | Alliance Cancer Specialists |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487923686 PECOS PAC ID: 7214194091 Enrollment ID: O20120207000029 |
News Archive
Researchers at the University of Warwick have found that sexual orientation has a real effect on how we perform mental tasks such as navigating with a map in a car but that old age does not discriminate on grounds of sexual orientation and withers all men's minds alike just ahead of women's.
Arlington Medical Resources, a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that electrical cardioversion usage patterns in Europe differed dramatically by country in the fourth quarter of 2009. While ECV represented almost half of all cardioversion attempts in Germany, in Spain ECV accounted for only 13% of cardioversion attempts.
MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, announced today its record revenue results for the third quarter of 2015, its guidance for the fourth quarter of 2015, and that the Company has secured a $50 million Senior Secured Credit Facility.
An assay that identifies a peculiar but important abnormality in cancer cells has been developed and validated by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the first patient has been dosed in a Phase 1/2 study of its vaccine candidate, CDX-1401, in patients with malignant solid tumors that express NY-ESO-1. CDX-1401 is a fully human monoclonal antibody designed to selectively deliver the NY-ESO-1 antigen to dendritic cells to generate a robust immune response against cancer cells expressing NY-ESO-1.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas Robert Drames, DO 1000 Floral Vale Blvd, Suite 125, Yardley, PA 19067-5569 Ph: (215) 785-9500 | Dr Thomas Robert Drames, DO 1000 Floral Vale Blvd, Suite 125, Yardley, PA 19067-5569 Ph: (215) 785-9500 |
News Archive
Researchers at the University of Warwick have found that sexual orientation has a real effect on how we perform mental tasks such as navigating with a map in a car but that old age does not discriminate on grounds of sexual orientation and withers all men's minds alike just ahead of women's.
Arlington Medical Resources, a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that electrical cardioversion usage patterns in Europe differed dramatically by country in the fourth quarter of 2009. While ECV represented almost half of all cardioversion attempts in Germany, in Spain ECV accounted for only 13% of cardioversion attempts.
MiMedx Group, Inc., the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental sectors of healthcare, announced today its record revenue results for the third quarter of 2015, its guidance for the fourth quarter of 2015, and that the Company has secured a $50 million Senior Secured Credit Facility.
An assay that identifies a peculiar but important abnormality in cancer cells has been developed and validated by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced that the first patient has been dosed in a Phase 1/2 study of its vaccine candidate, CDX-1401, in patients with malignant solid tumors that express NY-ESO-1. CDX-1401 is a fully human monoclonal antibody designed to selectively deliver the NY-ESO-1 antigen to dendritic cells to generate a robust immune response against cancer cells expressing NY-ESO-1.
› Verified 6 days ago
Robert Mogul, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 524 Cedar Hollow Dr, Yardley, PA 19067 Phone: 215-321-3561 | |
Dr. Brian Garriock Firth, MD, PHD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 1497 Brookfield Rd, Yardley, PA 19067 Phone: 215-579-2606 Fax: 215-579-2833 | |
Dr. Richard D Shusterman, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1000 Floral Vale Blvd, Suite 125, Yardley, PA 19067 Phone: 215-785-9500 | |
Harvey E Goldberg, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 777 Township Line Rd, Suite 200, Yardley, PA 19067 Phone: 215-860-0775 Fax: 215-860-4394 | |
Dr. Michael O'neill Montgomery, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 249 Forrest Rd, Yardley, PA 19067 Phone: 215-428-0872 | |
Dr. Neil S Silber, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 301 Oxford Valley Rd, Suite 305-b Makefield Executive Quarters, Yardley, PA 19067 Phone: 216-493-6444 Fax: 215-493-5274 |